Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 2;24(17):13591.
doi: 10.3390/ijms241713591.

HLA-F and LILRB1 Genetic Polymorphisms Associated with Alloimmunisation in Sickle Cell Disease

Emmanuelle Bernit  1 , Estelle Jean  2 , Bastien Marlot  3 , Laurine Laget  4 , Caroline Izard  4 , Isabelle Dettori  4 , Sophie Beley  3 , Isabelle Gautier  2 , Imane Agouti  2 , Coralie Frassati  3   4 , Pascal Pedini  3   4 , Christophe Picard  3   4 , Julien Paganini  5 , Jacques Chiaroni  3   4 , Julie Di Cristofaro  3   4
Affiliations

HLA-F and LILRB1 Genetic Polymorphisms Associated with Alloimmunisation in Sickle Cell Disease

Emmanuelle Bernit et al. Int J Mol Sci. .

Abstract

Red blood cell (RBC) transfusion remains a critical component in caring for the acute and chronic complications of sickle cell disease (SCD). Patient alloimmunisation is the main limitation of transfusion, which can worsen anaemia and lead to delayed haemolytic transfusion reaction or transfusion deadlock. Although biological risk factors have been identified for immunisation, patient alloimmunisation remains difficult to predict. We aimed to characterise genetic alloimmunisation factors to optimise the management of blood products compatible with extended antigen matching to ensure the self-sufficiency of labile blood products. Considering alloimmunisation in other clinical settings, like pregnancy and transplantation, many studies have shown that HLA Ib molecules (HLA-G, -E, and -F) are involved in tolerance mechanism; these molecules are ligands of immune effector cell receptors (LILRB1, LILRB2, and KIR3DS1). Genetic polymorphisms of these ligands and receptors have been linked to their expression levels and their influence on inflammatory and immune response modulation. Our hypothesis was that polymorphisms of HLA Ib genes and of their receptors are associated with alloimmunisation susceptibility in SCD patients. The alloimmunisation profile of thirty-seven adult SCD patients was analysed according to these genetic polymorphisms and transfusion history. Our results suggest that the alloimmunisation of SCD patients is linked to both HLA-F and LILRB1 genetic polymorphisms located in their regulatory region and associated with their protein expression level.

Keywords: HLA-F; KIR3DS1; LILRB1; alloimmunisation; genetic polymorphisms; sickle cell disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Kavanagh P.L., Fasipe T.A., Wun T. Sickle Cell Disease: A Review. JAMA. 2022;328:57–68. doi: 10.1001/jama.2022.10233. - DOI - PubMed
    1. Bender M.A. Sickle Cell Disease. In: Adam M.P., Mirzaa G.M., Pagon R.A., Wallace S.E., Bean L.J.H., Gripp K.W., Amemiya A., editors. GeneReviews((R)) GeneReviews®; Seattle, WA, USA: 1993.
    1. Ashley-Koch A., Yang Q., Olney R.S. Sickle Hemoglobin (Hb S) Allele and Sickle Cell Disease: A HuGE Review. Am. J. Epidemiol. 2000;151:839–845. doi: 10.1093/oxfordjournals.aje.a010288. - DOI - PubMed
    1. Habara A., Steinberg M.H. Minireview: Genetic basis of heterogeneity and severity in sickle cell disease. Exp. Biol. Med. 2016;241:689–696. doi: 10.1177/1535370216636726. - DOI - PMC - PubMed
    1. Origa R. beta-Thalassemia. Genet. Med. 2017;19:609–619. doi: 10.1038/gim.2016.173. - DOI - PubMed